1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Asmacure appoints Martin Driscoll CEO

 
• By Gemma Sharman

Asmacure, a clinical-stage biopharma company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, has appointed Martin Driscoll chief executive officer. Mr Driscoll was previously CEO and a director of Javelin Pharmaceuticals and will succeed Dr Luc Vachon, who is leaving the company to pursue other business ventures.

Asmacure, a clinical-stage biopharma company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, has appointed Martin Driscoll chief executive officer. Mr Driscoll was previously CEO and a director of Javelin Pharmaceuticals and will succeed Dr Luc Vachon, who is leaving the company to pursue other business ventures.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

More from Therapeutic Category

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.